To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Inhibrx, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Inhibrx, Inc. (“Inhibrx” or the “Company”)(NASDAQ: INBX), in connection with its acquisition by Aventis Inc.  Under the merger agreement, the Company’s shareholders will receive: (i) $30.00 per share; (ii) one contingent value right (“CVR”) per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone; and (iii) one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held.

Weiss Law is investigating whether (i) the Inhibrx board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the merger consideration adequately compensates Inhibrx shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com